Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
Open accessThe DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index; 48 of the 126 sources its claims cite were checked for support.
Abstract
Improvements in sensor accuracy, greater convenience and ease of use, and expanding reimbursement have led to growing adoption of continuous glucose monitoring (CGM). However, successful utilization of CGM technology in routine clinical practice remains relatively low. This may be due in part to the lack of clear and agreed-upon glycemic targets that both diabetes teams and people with diabetes can work toward. Although unified recommendations for use of key CGM metrics have been established in three separate peer-reviewed articles, formal adoption by diabetes professional organizations and guidance in the practical application of these metrics in clinical practice have been lacking. In February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address this issue. This article summarizes the ATTD consensus recommendations for relevant aspects of CGM data utilization and reporting among the various diabetes populations.
Overview
CoChat Summary
TL;DR
An international ATTD consensus panel recommends standardized continuous glucose monitoring (CGM) time-in-range targets to complement A1C for type 1/type 2 diabetes, older/high-risk individuals, and pregnancy. It defines target TIR, TBR, and TAR cutpoints and cites evidence linking TIR to A1C and diabetes complications.
Key findings
- For type 1/type 2 diabetes, the panel recommends TIR 70–180 mg/dL >70% (>16 h 48 min), TBR <70 mg/dL <4% (<1 h), TBR <54 mg/dL <1% (<15 min), TAR >180 mg/dL <25% (<6 h), and TAR >250 mg/dL <5% (<1 h 12 min). For older/high-risk individuals, TIR target is >50% (>12 h), TBR <70 mg/dL <1% (<15 min), and TAR >250 mg/dL <10% (<2 h 24 min).
- For pregnancy in type 1 diabetes, the target range is 63–140 mg/dL (3.5–7.8 mmol/L), with TIR >70% (>16 h 48 min), TBR <63 mg/dL <4% (<1 h), TBR <54 mg/dL <1% (<15 min), and TAR >140 mg/dL <25% (<6 h); pregnancy type 2/GDM targets were not included because of limited evidence.
- TIR relates to A1C: TIR 70% and 50% corresponded with A1C approximately 7% (53 mmol/mol) and 8% (64 mmol/mol), respectively; every 10% increase in TIR corresponded to about 0.5% (5.5 mmol/mol) A1C reduction in Beck et al. (n=545 type 1 diabetes) and about 0.8% (8.7 mmol/mol) in Vigersky et al. (n=1,137 type 1/type 2).
- In DCCT data, hazard for retinopathy progression increased by 64% for each 10% reduction in TIR, and microalbuminuria development increased by 40%; in 3,262 people with type 2 diabetes, more advanced diabetic retinopathy was associated with less time in target range. The panel also recommends 14 days of CGM data, >70% CGM active, and %CV target <36% (some studies suggest <33%).
Methods
- Consensus process: in February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes expert in CGM; subgroups reviewed literature and presented evidence-based recommendations to the full panel for voting.
- Data/sample: no new primary trial was conducted; the paper synthesizes cited studies, including Beck et al. (n=545 type 1 diabetes), Vigersky et al. (n=1,137 type 1/type 2), Lu et al. (3,262 type 2 diabetes), DCCT analyses, and pregnancy CGM studies.
- Main analysis: narrative evidence synthesis and expert consensus on CGM metrics, time-in-range cutpoints, and standardized Ambulatory Glucose Profile reporting; no formal meta-analysis or systematic review is described.
Limitations
- The paper states that long-term trials demonstrating how CGM metrics relate to and/or predict clinical outcomes have not been conducted, and the evidence is suggestive; pregnancy percentages are based on limited evidence and more research is needed.
- The paper states there is no evidence regarding time in range for older and/or high-risk individuals, and CGM targets for women with GDM or type 2 diabetes in pregnancy were not included because of lack of evidence.
- Evident from the text: recommendations are consensus/expert opinion rather than a systematic review, and the consensus meeting/manuscript was funded by ATTD with support from multiple industry sponsors; many panel members report industry consulting, speaking, research, or advisory relationships.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
16 Valid · 14 Not valid · 24 Not checked · 13 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In individuals with type 1 diabetes, correlations are weaker for hypoglycemia and glycemic variability; however, these correlations have not been shown to increase with longer sampling periods (42).”
What the sources say
- Disputedcites [42] 41. Xing D, Kollman C, Beck RW, et al. Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring. Diabetes Technol Ther 2011;13:351-358. sourceExperimental — accuracy not yet measured
In type 1 diabetes, the Results (Table 2; page unavailable) show weaker correlations for hypoglycemia and glycemic variability than for mean glucose at 15 days. But they also show that both correlations increase as sampling extends from 3 to 15 days, contrary to the citing sentence’s claim that an increase with longer sampling has not been shown. The paper does not frame this analysis as >70% CGM use over 14 days. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In individuals with type 1 diabetes, correlations are weaker for hypoglycemia and glycemic variability; however, these correlations have not been shown to increase with longer sampling periods (42).”
What the sources say
- Disputedcites [42] 41. Xing D, Kollman C, Beck RW, et al. Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring. Diabetes Technol Ther 2011;13:351-358. sourceExperimental — accuracy not yet measured
The Results (Table 2; page unavailable) show that correlations with the full three-month data increased as sampling lengthened for both hypoglycemia and glycemic variability. From 3 to 15 days, r² rose from 0.32 to 0.66 for values ≤70 mg/dL and from 0.36 to 0.70 for coefficient of variation—the opposite of the attributed claim. (LLM, conf=0.93)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The first longitudinal CGM data demonstrated a 13percentage point increase in TIR (43% to 56% TIR 70-140 mg/dL [3.9-7.8 mmol/L]) (61).”
What the sources say
- Disputedcites [61] 62. Stewart ZA, Wilinska ME, Hartnell S, et al. Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. N Engl J Med. 2016;375(7):644-654. sourceExperimental — accuracy not yet measured
The Study Outcomes report different CGM time-in-range results: 59.5% to 74.7% overnight and 56.8% to 66.3% over 24 hours with closed-loop therapy. The paper defines its target range as 63–140 mg/dL, not 70–140 mg/dL; it does not report the claimed increase from 43% to 56%. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Numerous studies have demonstrated significant clinical benefits of CGM use in people with diabetes regardless of insulin delivery method (1-15).”
What the sources say
- Not checked — no full text of the sourcecites [1] 1. Lind M, Polonsky W, Hirsch IB. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA 2017;317(4):379-387 source
- Partly supportedcites [2] 2. Aleppo G, Ruedy KJ, Riddlesworth TD, et al. REPLACE-BG: A randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes. Diabetes Care 2017;40(4):538-545. sourceExperimental — accuracy not yet measured
The Introduction reports that several randomized trials found CGM benefits, including reduced HbA1c and hypoglycemia, particularly in adults with type 1 diabetes. But the Conclusions say this trial included only insulin-pump users; extending its results to people using injections is described as reasonable, not demonstrated. The paper therefore does not establish benefits regardless of insulin delivery method or across all people with diabetes. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [3] 3. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA 2017; 317:371-378. source
- Not checked — no full text of the sourcecites [4] 4. Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med 2017;167:365-374. source
- Not checked — no full text of the sourcecites [5] 5. Polonsky WH, Hessler D, Ruedy KJ, Beck RW, for the DIAMOND Study Group. The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: further findings from the DIAMOND randomized clinical trial. Diabetes Care 2017; 40:736-741. source
- Supportedcites [6] 6. ϲ͘ ŠŽƵƉĂů J͕ PĞƚƌƵǎĞůŬŽǀĄ L͕ FůĞŬĂē M͕ Ğƚ Ăů͘ CŽŵƉĂƌŝƐŽŶ ŽĨ ĚŝĨĨĞƌĞŶƚ ƚƌĞĂƚŵĞŶƚ ŵŽĚĂůŝƚŝĞƐ ĨŽƌ type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: a COMISAIR study. Diabetes Technol Ther. 2016;18(9):532-538. source
The Discussion reports significant glycemic benefits from real-time CGM that were comparable with pump (CSII) and injection (MDI) therapy. The study concerns people with type 1 diabetes. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [7] 7. van Beers CA, DeVries JH, Kleijer SJ, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, openlabel, crossover trial. Lancet Diabetes Endocrinol. 2016;4(11):893-902. source
- Not checked — no full text of the sourcecites [8] 8. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kr ger J, Weitgasser R. Novel glucose-sensing technology and hypoglycemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 2016;388:2254-2263. source
- Partly supportedcites [9] 9. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulintreated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther 2017;8(1):55-73. sourceExperimental — accuracy not yet measured
The Results report significant reductions in hypoglycemic events with flash glucose monitoring in adults with insulin-treated type 2 diabetes, supporting a clinical benefit. The Results also state that 95% of participants used an insulin pen or syringe and 5% used continuous subcutaneous insulin infusion; the paper does not establish that the benefit held regardless of insulin delivery method. No page numbers are available in our copy. (LLM, conf=0.85)
- Partly supportedcites [10] 10. Choudhary P, Olsen BS, Conget I, et al. Hypoglycemia prevention and user acceptance of an insulin pump system with predictive low glucose management. Diabetes Technol Ther 2016;18(5):288-291. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says the CGM-based MiniMed 640G pump system can help patients with type 1 diabetes avoid hypoglycemia. But this short, uncontrolled study examined a predictive pump-suspension system, not CGM use regardless of insulin delivery method; it does not establish a benefit across delivery methods or isolate the benefit of CGM itself. (LLM, conf=0.88)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A1C is currently recognized as the key surrogate marker for the development of longterm diabetes complications in people with type 1 and type 2 diabetes and has been used the primary endpoint for many CGM studies (1; 3; 4; 6; 32; 33).”
What the sources say
- Not checked — no full text of the sourcecites [1] 1. Lind M, Polonsky W, Hirsch IB. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA 2017;317(4):379-387 source
- Not checked — no full text of the sourcecites [3] 3. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA 2017; 317:371-378. source
- Not checked — no full text of the sourcecites [4] 4. Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med 2017;167:365-374. source
- Could not verifycites [6] 6. ϲ͘ ŠŽƵƉĂů J͕ PĞƚƌƵǎĞůŬŽǀĄ L͕ FůĞŬĂē M͕ Ğƚ Ăů͘ CŽŵƉĂƌŝƐŽŶ ŽĨ ĚŝĨĨĞƌĞŶƚ ƚƌĞĂƚŵĞŶƚ ŵŽĚĂůŝƚŝĞƐ ĨŽƌ type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: a COMISAIR study. Diabetes Technol Ther. 2016;18(9):532-538. sourceExperimental — accuracy not yet measured
The Prespecified outcomes section (page unavailable) identifies HbA1c as this type 1 diabetes study’s primary endpoint. Neither that section nor the Discussion passages establish that A1C is the key surrogate marker for long-term complications in people with both type 1 and type 2 diabetes. Searches for that surrogate-marker relationship and for complications found no passage stating it. (LLM, conf=0.72)
- Partly supportedcites [33] 32. Battelino T, Conget I, Olsen B, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 2012;55(12):3155-3162. sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) links near-normal glycaemia with reduced complication risk in type 1 diabetes, and Methods > Outcome measure (page unavailable) uses HbA1c as this trial’s primary endpoint. The paper does not establish HbA1c as the key surrogate marker for long-term complications in both type 1 and type 2 diabetes. (LLM, conf=0.81)
- Could not verifycites [32] 31. Novodvorsky P, Bernjak A, Chow E, et al. Diurnal differences in risk of cardiac arrhythmias during spontaneous hypoglycemia in young people with type 1 diabetes. Diabetes Care 2017;40:655 ʹ 662. sourceExperimental — accuracy not yet measured
The Baseline Assessment section says HbA1c was measured at the start of monitoring, but does not describe it as a surrogate marker for long-term complications. The Research Design and Methods section examines arrhythmias during hypoglycemia, not A1C as a primary endpoint in CGM studies. Searches for the surrogate-marker and primary-endpoint claims found no supporting passage in our copy. (LLM, conf=0.76)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
37 more claims · 16 with their cited sources checked
Create a free account to see all 67 claims and to verify the 4 references still open.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 13
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With the advent of newer studies of CGM in noninsulin‐treated individuals and increasing uptake, the utility of CGM is progressively being endorsed in this population.”
From Continuous glucose monitoring in noninsulin‐treated type 2 diabetes: A critical review of reported trials with an updated systematic review and meta‐analysis of randomised controlled trials (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypoglycaemia is associated with an increased risk of vascular events, explaining recent consensus advocating hypoglycaemic exposure at <1% (i.e.<15 min/day) in individuals at high CV risk.137,138”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [138]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Considering the older age of participants and comorbid conditions reported, the mean HbA1c, GMI, TIR, and TBR results (8.0%, 7.6%, 56%, and 1.0% at 6 months, respectively) demonstrate close adherence to established glycemic targets (23, 24, 38).”
From Observed Glycemic and Psychosocial Benefits in the Prospective Bigfoot Unity Real World Study: A 6-Month Analysis (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Avaiable data suggest that such systems can increase TIR and reduce hypoglycemia in patients with DGP, with improvements comparable to those observed in individuals without gastrointestinal complications, although data remain limited and largely observational [153–157].”
From Diabetic gastroparesis: pathophysiology and impact on insulin timing choices (2026) · cites this paper as [156]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A subsequent international consensus defined targets for most of the measures on the AGP that would correspond to individualized HbA 1c targets (193).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [193]
Experimental — accuracy not yet measured
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ FIGURES / TABLES · p. 4
“2 Figures / 3 Tables”
§ Relationship Between TIR and A1C · p. 15
“Table 4. Estimate of A1C for a given TIR level based on type 1 diabetes and type 2 diabetes studies”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Time in Ranges · p. 11
“Table 4. Consensus guidance on cutpoints for assessment of glycemic control: Pregnancy”
§ Relationship Between TIR and A1C · p. 15
“Table 4. Estimate of A1C for a given TIR level based on type 1 diabetes and type 2 diabetes studies”
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
Self-citationState of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., Maahs, D. M., Tamborlane, W. V., Bergenstal, R., Smith, E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0384 · Cited by 1,907
Self-citationIsmail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Self-citationBeck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185 · cited 1×
“A1C is currently recognized as the key surrogate marker for the development of long-termdiabetes complications in people with type 1 and type 2 diabetes and has been used as the primary end point for many CGM studies (1,3,4,6,33,34).”
BackgroundSelf-citationBolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893
Cited by
Items 201–300 of 3,959
Miller, K. M., Kanapka, L. G., Rickels, M. R., Ahmann, A. J., Aleppo, G., Ang, L., Bhargava, A., Bode, B. W., Carlson, A., Chaytor, N. S., et al. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0503 · Cited by 73
Self-citationMissed and Mistimed Insulin Doses in People with Diabetes: A Systematic Literature Review
Robinson, S., Newson, R. S., Liao, B., Kennedy-Martin, T., & Battelino, T. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0164 · Cited by 73
“63,64 In the management of diabetes, it is important to move away from historical data review and response to an ever-changing clinical situation and move toward dynamic, (near) real-time behavioral changes.”
Self-citationOffline reinforcement learning for safer blood glucose control in people with type 1 diabetes
Emerson, H., Guy, M., & McConville, R. (2023) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2023.104376 · Cited by 116
Sevil, M., Rashid, M. M., Hajizadeh, I., Park, M., Quinn, L., & Çınar, A. (2021) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2020.3049109 · Cited by 86
Application of Telemedicine in Diabetes Care: The Time is Now
Aberer, F., Hochfellner, D. A., & Mader, J. K. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00996-7 · Cited by 90
“assessing glycemic control in diabetic individuals who use such systems [17, 18].”
BackgroundOser, T. K., Hall, T. L., Dickinson, L. M., Callen, E., Carroll, J. K., Nease, D. E., Michaels, L., & Oser, S. M. (2022) · The Annals of Family Medicine · doi:10.1370/afm.2876 · Cited by 72
Unwin, D., Delon, C., Unwin, J., Tobin, S., & Taylor, R. (2023) · BMJ Nutrition, Prevention & Health · doi:10.1136/bmjnph-2022-000544 · Cited by 72
Karges, B., Tittel, S. R., Bey, A., Freiberg, C., Klinkert, C., Kordonouri, O., Thiele‐Schmitz, S., Schröder, C., Steigleder‐Schweiger, C., & Holl, R. W. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00061-x · Cited by 91
Self-citationLind, N., Christensen, M. B., Hansen, D. L., & Nørgaard, K. (2024) · Diabetes Care · doi:10.2337/dc23-2194 · Cited by 71
Self-citationMathieu, C., Rudofsky, G., Phillip, M., Araki, E., Lind, M., Arya, N., Thorén, F., Scheerer, M. F., Iqbal, N., & Dandona, P. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14060 · Cited by 71
“This was supported by CGM data obtained in the DEPICT trials, where no notable differences were observed at week 24 with regards to the percentage of glucose values within the ranges indicating hypoglycaemia (≤3.9 mmol/L [≤70 mg/dL] or ≤3.0 mmol/L [≤54 mg/dL]) over 24 hours in people who received dapagliflozin compare…”
InfluentialSelf-citationA review of flash glucose monitoring in type 2 diabetes
Krakauer, M., Botero, J. F., Lavalle-González, F. J., Proietti, A., & Barbieri, D. E. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00654-3 · Cited by 71
Faulds, E. R., Boutsicaris, A., Sumner, L., Jones, L., McNett, M., Smetana, K. S., May, C. C., Buschur, E., Exline, M. C., Ringel, M. D., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab409 · Cited by 71
“Safety measures including frequency of hypoglycemia (POC glucose <55 mg/dL and <70 mg/dL) and daily percent time in range (TIR) (70-180 mg/dL), time above range (>180 mg/dL and >250 mg/dL), and time below range (<54 mg/dL and <70 mg/dL) were aggregated from discrete CGM values (30).”
MethodDigital biomarkers: 3PM approach revolutionizing chronic disease management — EPMA 2024 position
Smokovski, I., Steinle, N., Behnke, A., Bhaskar, S. M. M., Grech, G., Richter, K., Niklewski, G., Birkenbihl, C., Parini, P., Andrews, R. J., et al. (2024) · The EPMA Journal · doi:10.1007/s13167-024-00364-6 · Cited by 88
Forlenza, G. P., Carlson, A. L., Galindo, R. J., Kruger, D. F., Levy, C. J., McGill, J. B., Umpierrez, G., & Aleppo, G. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0206 · Cited by 70
“CGM metrics are calculated and presented as recommended by the international consensus on time in range and using the American Diabetes Association (ADA) targets for TIR metrics.(26) Percent time in closed-loop automation was calculated as the percentage of the total basal rates delivered by the pump, in 5-min increme…”
MethodThe Role of Glycemic Variability in Cardiovascular Disorders
Alfieri, V., Myasoedova, V. A., Vinci, M. C., Rondinelli, M., Songia, P., Massaiu, I., Cosentino, N., Moschetta, D., Valerio, V., Ciccarelli, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168393 · Cited by 85
“, time per day within target glucose range (TIR), time below target glucose range (TBR), and time above target glucose range (TAR) [23].”
BackgroundDuckworth, C., Guy, M. J., Kumaran, A., O’Kane, A. A., Ayobi, A., Chapman, A., Marshall, P., & Boniface, M. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221103561 · Cited by 75
“…daily risk range, 50 %coefficient of variation, 51 level 2 hypoglycemia (% of readings or time < 54 mg/dL), level 2 hyperglycemia (% of readings or time > 250 mg/dL), 52 and low/high blood glucose index 53,54 along with our baseline of standard deviation is likely to improve model performance.”
Meulemeester, J. D., Charleer, S., Visser, M. M., Block, C. E. M. D., Mathieu, C., & Gillard, P. (2024) · Diabetologia · doi:10.1007/s00125-024-06171-y · Cited by 89
“Based on the recommendations of the international consensus on CGM use, time in range (TIR: 3.9–10.0 mmol/l) has been adopted in clinical practice as a key metric in glycaemic management and as an endpoint in clinical trials [7].”
InfluentialSelf-citationMunan, M., Oliveira, C. L. P., Marcotte-Chénard, A., Rees, J. L., Prado, C. M., Riesco, E., & Boulé, N. G. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00495 · Cited by 70
“Recent international consensus statements (6) suggest values of 3.”
BackgroundMethodMattishent, K., & Loke, Y. K. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.571568 · Cited by 69
Li, F., Zhang, Y., Li, H., Lu, J., Jiang, L., Vigersky, R. A., Zhou, J., Wang, C., Bao, Y., & Jia, W. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108289 · Cited by 69
Self-citationMesa, A., Viñals, C., Pueyo, I., Roca, D., Vidal, M., Giménez, M., & Conget, I. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108354 · Cited by 69
Scott, E. S., Januszewski, A. S., O’Connell, R., Fulcher, G., Scott, R., Kesaniemi, A., Wu, L., Colagiuri, S., Keech, A., & Jenkins, A. J. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa361 · Cited by 70
Shah, V. N., Kanapka, L. G., Aktürk, H. K., Polsky, S., Forlenza, G. P., Kollman, C., Beck, R. W., & Snell‐Bergeon, J. K. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0486 · Cited by 79
Self-citationToschi, E., Slyne, C., Sifre, K., O’Donnell, R., Greenberg, J., Atakov-Castillo, A., Carl, S., & Munshi, M. (2020) · Diabetes Care · doi:10.2337/dc20-0016 · Cited by 69
Jendle, J., Ericsson, Å., Gundgaard, J., Møller, J. B., Valentine, W. J., & Hunt, B. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00980-1 · Cited by 68
Godoi, A., Reis Marques, I., Padrão, E. M. H., Mahesh, A., Hespanhol, L. C., Riceto Loyola Júnior, J. E., de Souza, I. A. F., Moreira, V. C. S., Silva, C. H., Miyawaki, I. A., et al. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01144-4 · Cited by 67
“Although HbA1c is currently the metric of choice by most endocrinology and diabetes societies [54, 55], TIR and HbA1c should be used as complementary parameters to guide care [56] and allow evaluation in clinical research [57].”
BackgroundBeato-Víbora, P. I., Gallego-Gamero, F., Lázaro-Martín, L., Romero-Pérez, M. D. M., & Arroyo-Díez, F. J. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0400 · Cited by 66
“21 Nevertheless, similarly to previous reports with other hybrid closed-loop systems, 22 in the subgroup of patients with high hypoglycemia frequency and risk, from our cohort, the frequency of hypo-glycemia was reduced and HbA1c also was reduced.”
Jennings, P., & Hussain, S. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819894296 · Cited by 66
“A substantial proportion of the real-world experience of hybrid closedloop systems has come from the DIY APS community.8,9 Melmer and colleagues undertook a secondary analysis of 19 495 days (53.4 years) of CGM data donated by 80 OpenAPS users.15 They found individuals using DIY APS were achieving levels of glycemic c…”
InfluentialBasics and use of continuous glucose monitoring (CGM) in diabetes therapy
Freckmann, G. (2020) · Journal of Laboratory Medicine · doi:10.1515/labmed-2019-0189 · Cited by 87
“Besides education Table 2: Key metrics for CGM data analysis and reporting [36].”
BackgroundMethodInfluentialReal-World Evidence and Glycemic Improvement Using Dexcom G6 Features
Aktürk, H. K., Dowd, R., Shankar, K., & Derdzinski, M. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0654 · Cited by 73
Current Status and Emerging Options for Automated Insulin Delivery Systems
Forlenza, G. P., & Lal, R. A. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0514 · Cited by 67
Brener, A., Mazor‐Aronovitch, K., Rachmiel, M., Levek, N., Barash, G., Pinhas‐Hamiel, O., Lebenthal, Y., & Landau, Z. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01596-4 · Cited by 67
“These definitions were according to the international consensus on CGM interpretation [17].”
MethodPassanisi, S., Piona, C. A., Salzano, G., Marigliano, M., Bombaci, B., Morandi, A., Alibrandi, A., Maffeis, C., & Lombardo, F. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0373 · Cited by 69
Gibb, F. W., McKnight, J. A., Clarke, C., & Strachan, M. W. J. (2020) · Diabetologia · doi:10.1007/s00125-020-05099-3 · Cited by 74
Time in range centered diabetes care
Dovč, K., & Battelino, T. (2021) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.30.1 · Cited by 70
“Recently, several major international societies formally endorsed an international consensus report on clinical targets for CGM data (58); notably, the consensus participants included also individuals with diabetes outside the medical profession.”
BackgroundMethodInfluentialSelf-citationCobry, E. C., Bisio, A., Wadwa, R. P., & Breton, M. D. (2022) · Diabetes Care · doi:10.2337/dc21-1778 · Cited by 64
Glucose variability: a new risk factor for cardiovascular disease
Belli, M., Bellia, A., Sergi, D., Barone, L., Lauro, D., & Barillà, F. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02097-w · Cited by 76
2023 Guidelines on the management of patients with diabetes - a position of Diabetes Poland
Araszkiewicz, A., Bandurska-Stankiewicz, E. M., Borys, S., Budzynski, A. Z., Cyganek, K., Cypryk, K., Czech, A., Czupryniak, L., Drzewoski, J., Dzida, G. J., et al. (2023) · Current Topics in Diabetes · doi:10.5114/ctd/160061 · Cited by 85
Predictors of Time-in-Range (70–180 mg/dL) Achieved Using a Closed-Loop Control System
Schoelwer, M. J., Kanapka, L. G., Wadwa, R. P., Breton, M. D., Ruedy, K. J., Ekhlaspour, L., Forlenza, G. P., Cobry, E. C., Messer, L. H., Cengiz, E., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0646 · Cited by 63
Self-citationExpanding the Role of Continuous Glucose Monitoring in Modern Diabetes Care Beyond Type 1 Disease
Klupa, T., Czupryniak, L., Dzida, G. J., Fichna, P., Jarosz-Chobot, P. A., Gumprecht, J., Myśliwiec, M., Szadkowska, A., Bomba-Opon, D. A., Czajkowski, K., et al. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01431-3 · Cited by 97
Pleus, S., Baumstark, A., Jendrike, N., Mende, J., Link, M., Zschornack, E., Haug, C., & Freckmann, G. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001067 · Cited by 63
Diabetes technology in the inpatient setting for management of hyperglycemia
Davis, G. M., Galindo, R. J., Migdal, A. L., & Umpierrez, G. E. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.11.002 · Cited by 62
Grace, T., & Salyer, J. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0212 · Cited by 64
“Importantly, these improvements were achieved while patients maintained established targets for %TBR.(18) Our findings of improved glycemic control are consistent with earlier studies of T2D patients treated with or without intensive insulin treatment.”
ResultStandardization process of continuous glucose monitoring: Traceability and performance
Freckmann, G., Nichols, J. H., Hinzmann, R., Klonoff, D. C., Ju, Y., Diem, P., Makris, K., & Slingerland, R. J. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.12.025 · Cited by 62
Glycaemic variability: The under‐recognized therapeutic target in type 1 diabetes care
Wilmot, E. G., Choudhary, P., Leelarathna, L., & Baxter, M. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13842 · Cited by 72
Zhu, T., Kuang, L., Piao, C., Zeng, J., Li, K., & Georgiou, P. (2024) · IEEE Transactions on Biomedical Circuits and Systems · doi:10.1109/tbcas.2023.3348844 · Cited by 75
“For individuals with T1D or T2D, they typically spend approximately 30% of their time in hypoglycemia or hyperglycemia range [53].”
BackgroundA Comparative Analysis of Glycemic Metrics Derived From Three Continuous Glucose Monitoring Systems
Freckmann, G., Wehrstedt, S., Eichenlaub, M., Pleus, S., Link, M., Jendrike, N. R. M., Öter, Ş., Brandt, D., Haug, C., & Waldenmaier, D. (2025) · Diabetes Care · doi:10.2337/dc25-0129 · Cited by 89
Nathanson, D., Svensson, A.-M., Miftaraj, M., Franzén, S., Bolinder, J., & Eeg-Olofsson, K. (2021) · Diabetologia · doi:10.1007/s00125-021-05437-z · Cited by 61
Boscari, F., & Avogaro, A. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09635-3 · Cited by 80
“[74, 75] The availability of these devices has changed the metric to assess glucose control: the possibility to visualize daily glucose profiles have shifted the gold standard parameter for metabolic control HBA1c to parameters such as time in target range (TIR), time spent between 70 and 180 mg/ dl, which have update…”
BackgroundBenhalima, K., Beunen, K., Siegelaar, S. E., Painter, R., Murphy, H. R., Feig, D. S., Donovan, L. E., Polsky, S., Buschur, E., Levy, C. J., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00116-x · Cited by 61
Self-citationBiester, T., Muller, I., von dem Berge, T., Atlas, E., Nimri, R., Phillip, M., Battelino, T., Bratina, N., Dovc, K., Scheerer, M. F., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14258 · Cited by 61
“9-10 mg/dL) was achieved with dapagliflozin, which is well above the 5% change that was considered to be clinically significant in the recent consensus statement.(16) The results regarding the efficacy of glucose control compare favourably with those from studies performed with the same system without adjunct therapy.”
BackgroundResultSelf-citationManaging Diabetes in Pregnancy Before, During, and After COVID-19
Murphy, H. R. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0223 · Cited by 59
Self-citationGao, X., Feng, W., Zhu, Z., Wu, Z., Shi, L., Kan, S., Qiu, X., Guo, A., Chen, W., & Yin, K. (2021) · Advanced Materials Interfaces · doi:10.1002/admi.202002133 · Cited by 63
Eckstein, M. L., Weilguni, B., Tauschmann, M., Zimmer, R. T., Aziz, F., Sourij, H., & Moser, O. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112445 · Cited by 67
Guideline for the Management of Diabetes Mellitus in the Elderly in China (2024 Edition)
Guo, L., & Xiao, X. (2024) · Aging Medicine · doi:10.1002/agm2.12294 · Cited by 79
“According to international consensus, these indicators can be used as supplementary glycemic goals 28 (Table 4).”
BackgroundReal‐world performance of the MiniMed™ 670G system in Europe
Da Silva, J., Bosi, E., Jendle, J., Arrieta, A., Castaneda, J., Grossman, B., Cordero, T. L., Shin, J., & Cohen, O. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14424 · Cited by 60
“9 of less than 4% and an estimated HbA1c of less than 7%.(3) In addition, they are superior to the average glycaemia reported by several national registries,(6,7) and provide reassuring evidence for the efficacy of the system in a broader population.”
BackgroundSelf-citationReal-world evidence of automated insulin delivery system use
Considine, E. G., & Sherr, J. L. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0442 · Cited by 59
Monnier, L., Wojtusciszyn, A., Molinari, N., Colette, C., Renard, É., & Owens, D. R. (2020) · Diabetes Care · doi:10.2337/dc19-1549 · Cited by 68
Færch, K., Blond, M. B., Bruhn, L., Amadid, H., Vistisen, D., Clemmensen, K. K. B., Vainø, C. T. R., PEDERSEN, C. H., Tvermosegaard, M., Dejgaard, T. F., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05306-1 · Cited by 63
Amadou, C., Franc, S., Benhamou, P.-Y., Lablanche, S., Huneker, E., Charpentier, G., & Penfornis, A. (2021) · Diabetes Care · doi:10.2337/dc20-1809 · Cited by 59
Novel Biochemical Markers of Glycemia to Predict Pregnancy Outcomes in Women With Type 1 Diabetes
Meek, C. L., Tundidor, D., Feig, D. S., Yamamoto, J. M., SCOTT, E. M., Ma, D.-D., Halperin, J. A., Murphy, H. R., Corcoy, R., & the CONCEPTT collaborative group (2021) · Diabetes Care · doi:10.2337/dc20-2360 · Cited by 68
Self-citationPetrovski, G., Khalaf, F. A., Campbell, J., Day, E., Almajaly, D., Hussain, K., Pasha, M., Umer, F., Hamdan, M., & Khalifa, A. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-00996-7 · Cited by 73
Metas no tratamento do diabetes
de Almeida-Pititto, B., Rodrigues, M. L. D., de Moura, F. F., Lamounier, R. N., Vencio, S. A. C., Calliari, L. E., & Bertoluci, M. C. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-3 · Cited by 104
Shaw, J. L. V., Bannuru, R. R., Beach, L. A., ElSayed, N. A., Freckmann, G., Füzéry, A. K., Fung, A. W. S., Gilbert, J. D., Yun, H., Korpi-Steiner, N. L., et al. (2024) · Diabetes Care · doi:10.2337/dci24-0073 · Cited by 78
Digital Technology for Diabetes
Hughes, M. S., Addala, A., & Buckingham, B. (2023) · New England Journal of Medicine · doi:10.1056/nejmra2215899 · Cited by 59
Self-citationYoo, J. H., Kim, G., Lee, H. J., Sim, K. H., Jin, S.-M., & Kim, J. H. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109209 · Cited by 58
Fabris, C., Heinemann, L., Beck, R., Cobelli, C., & Kovatchev, B. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0236 · Cited by 58
Self-citationHayashi, A., Shimizu, N., Suzuki, A., Matoba, K., Momozono, A., Masaki, T., Ogawa, A., Moriguchi, I., Takano, K., Kobayashi, N., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0269 · Cited by 65
Avari, P., Lumb, A. N., Flanagan, D., Rayman, G. A., Misra, S., Dhatariya, K., & Choudhary, P. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221137338 · Cited by 76
MiniMed 780G™ in 2- to 6-Year-Old Children: Safety and Clinical Outcomes After the First 12 Weeks
Pulkkinen, M., Varimo, T. J., Hakonen, E. T., Harsunen, M. H., Hyvönen, M. E., Janér, J., Kiiveri, S., Laakkonen, H., Laakso, S. M., Wehkalampi, K., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0313 · Cited by 65
Beato-Víbora, P. I., Chico, A. I., Moreno-Fernández, J., Bellido, V., Nattero‐Chávez, L., César, M. J. P., Martínez‐Brocca, M. A., Giménez, M., Aguilera, E., Climent, E., et al. (2023) · Diabetes Care · doi:10.2337/dc23-1355 · Cited by 62
Sivaprasad, S., Wong, T. Y., Gardner, T. W., Sun, J. K., & Bressler, N. M. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00646-x · Cited by 77
“These features are central to the prediabetes or metabolic syndrome profile and may account for the development of DRD and peripheral neuropathies in persons with glucose intolerance but normal fasting glucose concentrations and HbA1c 84–87 .”
InfluentialMajithia, A. R., Kusiak, C. M., Armento Lee, A., Colangelo, F. R., Romanelli, R. J., Robertson, S., Miller, D. P., Erani, D. M., Layne, J. E., Dixon, R. F., et al. (2020) · Journal of Medical Internet Research · doi:10.2196/21778 · Cited by 58
“4 hours per day—is considered a clinically meaningful increase [17].”
BackgroundBisio, A., Brown, S. A., McFadden, R., Pajewski, M., Yu, P. L., DeBoer, M., Schoelwer, M. J., Bonner, H. G., Wakeman, C. A., Cherñavvsky, D. R., et al. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13164 · Cited by 57
“The glycemic outcomes for each condition are presented in Table 1 and are computed from CGM data as recommended by the recent international consensus on use of CGM.(30,31) The time in range (TIR) of 70–180 mg/dL improved significantly from SAP to AID (mean 50.”
MethodInfluentialTsoukas, M. A., Majdpour, D., Yale, J.-F., Fathi, A. E., Garfield, N., Rutkowski, J., Rene, J., Legault, L., & Haidar, A. (2021) · The Lancet Digital Health · doi:10.1016/s2589-7500(21)00139-4 · Cited by 58
Ng, S. M., Wright, N. P., Yardley, D., Campbell, F., Randell, T., Trevelyan, N., Ghatak, A., & Hindmarsh, P. C. (2023) · Diabetic Medicine · doi:10.1111/dme.15015 · Cited by 57
Fast-Acting Insulin Aspart Use with the MiniMed TM 670G System
Hsu, L., Buckingham, B., Basina, M., Ekhlaspour, L., von Eyben, R., Wang, J., & Lal, R. A. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0083 · Cited by 57
Self-citationDover, A. R., Ritchie, S. A., McKnight, J. A., Strachan, M. W. J., Zammitt, N. N., Wake, D. J., Forbes, S., Stimson, R. H., & Gibb, F. W. (2020) · Diabetic Medicine · doi:10.1111/dme.14374 · Cited by 56
“The percentage of individuals meeting the international consensus targets for time in range and time below range were also recorded [4].”
BackgroundType 1 diabetes and COVID-19: The “lockdown effect”
Aragona, M., Rodia, C., Bertolotto, A., Campi, F., Coppelli, A., GIANNARELLI, R., Bianchi, C., Dardano, A., & Prato, S. D. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108468 · Cited by 58
Beato-Víbora, P. I., Gallego-Gamero, F., Ambrojo-López, A., Gil-Poch, E., Martín-Romo, I., & Arroyo-Díez, F. J. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108986 · Cited by 56
Kariyawasam, D., Morin, C., Casteels, K., Le Tallec, C., Sfez, A., Godot, C., Huneker, E., Garrec, N., Benhamou, P.-Y., Polak, M., et al. (2022) · The Lancet Digital Health · doi:10.1016/s2589-7500(21)00271-5 · Cited by 57
“Findings from a randomised trial by De Bock and colleagues 34 in participants aged 12–25 years showed an increase in TIR during 6 months with a Minimed 670G Hybrid closed-loop system versus standard therapy, with or without CGM. Ekhlaspour and colleagues 20 did a randomised trial in children and adolescents (aged 6–18…”
MethodInfluentialSzmuilowicz, E. D., Levy, C. J., Buschur, E. O., & Polsky, S. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0540 · Cited by 58
“…psTIR, psTBR (pregnancy-specific time below range), and psTAR (pregnancy-specific time above range) for pregnant women with type 1 diabetes using CGM. 19 25 Glycemic targets for pregnancy are difficult to achieve, with only 61%–68% of women achieving the psTIR and only in the final weeks of pregnancy,…”
Top 10 Tips for Successfully Implementing a Diabetes Telehealth Program
Crossen, S. S., Raymond, J. K., & Neinstein, A. B. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0042 · Cited by 63
Wakasugi, S., Mita, T., Katakami, N., Okada, Y., Yoshii, H., Osonoi, T., Kuribayashi, N., Taneda, Y., Kojima, Y., Gosho, M., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01194-2 · Cited by 62
“After the SAP was published, the Advanced Technologies & Treatments for Diabetes Congress proposed some CGM-derived metrics as useful clinical targets that complement HbA1c [17].”
BackgroundMonnier, L., Colette, C., & Owens, D. R. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101225 · Cited by 64
Shafi, T., Zhu, X., Lirette, S. T., Rule, A. D., Mosley, T. H., Butler, K. R., Hall, M. E., Vaitla, P. K., Wynn, J. J., Tio, M. C., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m22-0610 · Cited by 60
“Food and Drug Administration (FDA) recommendation to use “Glucose Management Indicator,” or GMI, instead of estimated A1c for A1c calculated from continuous glucosemonitoring data (26).”
MethodSanusi, A. A., Xue, Y., McIlwraith, C. A., Howard, H., Brocato, B. E., Casey, B. M., Szychowski, J. M., & Battarbee, A. N. (2023) · Diabetes Care · doi:10.2337/dc23-0636 · Cited by 70
A Pilot Study of the Feasibility and Accuracy of Inpatient Continuous Glucose Monitoring
Nair, B. G., Dellinger, E. P., Flum, D. R., Rooke, G. A., & Hirsch, I. B. (2020) · Diabetes Care · doi:10.2337/dc20-0670 · Cited by 56
Self-citationPease, A., Lo, C., Earnest, A., Kiriakova, V., Liew, D., & Zoungas, S. (2020) · Diabetes Care · doi:10.2337/dc19-1785 · Cited by 71
“ied, these should provide at least 2weeks of CGM results (6), preferably with participant-level data.”
BackgroundPetrovski, G., Al Khalaf, F., Campbell, J., Umer, F., Almajaly, D., Hamdan, M., & Hussain, K. (2021) · Acta Diabetologica · doi:10.1007/s00592-020-01607-4 · Cited by 56
Wilson, D. M., Pietropaolo, S. L., Acevedo-Calado, M., Huang, S., Anyaiwe, D., Scheinker, D., Steck, A. K., Vasudevan, M. M., McKay, S. V., Sherr, J. L., et al. (2023) · Diabetes Care · doi:10.2337/dc22-1297 · Cited by 56
Self-citationGrassi, B., Gómez, A. M., Calliari, L. E., Franco, D., Raggio, M., Riera, F., Castro, M., McVean, J., van den Heuvel, T., Arrieta, A., et al. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15023 · Cited by 55
Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes
Kanapka, L. G., Wadwa, R. P., Breton, M. D., Ruedy, K. J., Ekhlaspour, L., Forlenza, G. P., Cengiz, E., Schoelwer, M. J., Jost, E., Carria, L., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1729 · Cited by 56
“However, this change, although statistically significant, is far below the threshold of 5% to be considered clinically meaningful (5).”
BackgroundSelf-citationBattelino, T., Bergenstal, R. M., Rodríguez, A., Fernández Landó, L., Bray, R., Tong, Z., & Brown, K. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00077-8 · Cited by 55
Self-citationTundidor, D., Meek, C. L., Yamamoto, J. M., Martínez-Brú, C., Gich, I. J., Feig, D. S., Murphy, H. R., Corcoy, R., On Behalf of the CONCEPTT Collaborative Group, Murphy, H. R., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0073 · Cited by 63
Self-citationAlgorithms for Automated Insulin Delivery: An Overview
Thomas, A., & Heinemann, L. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211008442 · Cited by 67
Self-citationVisser, M. M., Charleer, S., Fieuws, S., Block, C. E. M. D., Hilbrands, R., Huffel, L. V., Maes, T., Vanhaverbeke, G., Dirinck, E. L., Myngheer, N., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00352-7 · Cited by 63
Self-citationWilmot, E. G., Lumb, A. N., Hammond, P. J., Murphy, H. R., SCOTT, E. M., Gibb, F. W., Platts, J. K., & Choudhary, P. (2020) · Diabetic Medicine · doi:10.1111/dme.14433 · Cited by 58
“However, HbA1c also has limitations because it can be affected by external factors unrelated to blood glucose [14].”
BackgroundMethodInfluentialSelf-citationDiagnosis, Therapy and Follow-Up of Diabetes Mellitus in Children and Adolescents
Neu, A., Bürger-Büsing, J., Danne, T., Dost, A., Holder, M., Holl, R. W., Holterhus, P., Kapellen, T. M., Karges, B., Kordonouri, O., et al. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1018-8963 · Cited by 71
Self-citationDiabetes mellitus type 2 in adults
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Шамхалова, М. Ш., Sukhareva, O. Y., Galstyan, G. R., Tokmakova, A. Y., Nikonova, T. V., Surkova, E. V., Кононенко, И. В., et al. (2020) · Diabetes Mellitus · doi:10.14341/dm12507 · Cited by 69
Self-citation
Metadata
- Authors
- Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., Cobelli, C., Dassau, E., DeVries, J. H., Donaghue, K. C., Dovc, K., Doyle, F. J., Garg, S., Grunberger, G., Heller, S., Heinemann, L., Hirsch, I. B., Hovorka, R., Jia, W., Kordonouri, O., Kovatchev, B., Kowalski, A., Laffel, L., Levine, B., Mayorov, A., Mathieu, C., Murphy, H. R., Nimri, R., Nørgaard, K., Parkin, C. G., Renard, E., Rodbard, D., Saboo, B., Schatz, D., Stoner, K., Urakami, T., Weinzimer, S. A., & Phillip, M.
- Affiliations
- University of Ljubljana (SI)
- Kinderkrankenhaus auf der Bult (DE)
- Park Nicollet Health Services (US)
- King's College London (GB)
- Jaeb Center for Health Research (US)
- Vita-Salute San Raffaele University (IT)
- Stanford Medicine (US)
- American Diabetes Association (US)
- Close Concerns (United States) (US)
- University of Padua (IT)
- Harvard University (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- The University of Sydney (AU)
- Department of Pediatric Endocrinology, Diabetes and Metabolism, University Children’s Hospital, University Medical Centre Ljubljana, and Faculty of Medicine, University of Ljubljana, Slovenia
- University of Colorado Denver (US)
- Grunberger Diabetes Institute (US)
- University of Sheffield (GB)
- Science Consulting in Diabetes, Neuss, Germany
- University of Washington (US)
- University of Cambridge (GB)
- Shanghai Jiao Tong University (CN)
- University of Virginia (US)
- Breakthrough T1D (US)
- Joslin Diabetes Center (US)
- Endocrinology Research Center (RU)
- KU Leuven (BE)
- University of East Anglia (GB)
- Schneider Children's Medical Center (IL)
- Steno Diabetes Center Copenhagen (DK)
- CGParkin Communications, Inc., Henderson, NV
- Department of Endocrinology, Diabetes, and Nutrition, Montpellier University Hospital; Institute of Functional Genomics, University of Montpellier; and INSERM Clinical Investigation Centre, Montpellier, France
- Biomedical Informatics Consultants LLC, Potomac, MD
- DiaCare, Ahmedabad, Gujarat, India
- University of Florida (US)
- dQ&A Market Research, Inc., San Francisco, CA
- Nihon University (JP)
- Yale University (US)
- Tel Aviv University (IL)
- Corresponding author
- Battelino, Tadej
- ORCID
- Battelino, Tadej
- Danne, Thomas
- Bergenstal, Richard M.
- Amiel, Stephanie A.
- Beck, Roy
- Biester, Torben
- Bosi, Emanuele
- Buckingham, Bruce A.
- Cefalu, William T.
- Close, Kelly L.
- Cobelli, Claudio
- Dassau, Eyal
- DeVries, J. Hans
- Donaghue, Kim C.
- Doyle, Francis J.
- Garg, Satish
- Grunberger, George
- Heller, Simon
- Heinemann, Lutz
- Hirsch, Irl B.
- Hovorka, Roman
- Jia, Weiping
- Kordonouri, Olga
- Kovatchev, Boris
- Kowalski, Aaron
- Laffel, Lori
- Levine, Brian
- Mayorov, Alexander
- Mathieu, Chantal
- Murphy, Helen R.
- Nimri, Revital
- Nørgaard, Kirsten
- Parkin, Christopher G.
- Renard, Eric
- Rodbard, David
- Saboo, Banshi
- Schatz, Desmond
- Stoner, Keaton
- Urakami, Tatsuiko
- Weinzimer, Stuart A.
- Phillip, Moshe
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-06-08
- Volume
- 42
- Issue
- 8
- Pages
- 1593-1603
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC6973648
- OpenAlex
- W2948261890
- Cited by
- 4,237
- References
- 96
- Citations by year
- 2026: 716 · 2025: 649 · 2024: 655 · 2023: 575 · 2022: 619 · 2021: 556 · 2020: 398 · 2019: 61
- FWCI
- 215.44
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- UEA Digital Repository (University of East Anglia) (acceptedVersion)
- Pure Amsterdam UMC (acceptedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Lirias (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Leona M. and Harry B. Helmsley Charitable Trust
- University of Virginia
- Insulet Corporation
- MannKind Corporation
- Dexcom
- OPKO Health
- Steno Diabetes Center Copenhagen (SDCC 3.E Technology)
- National Institute for Health and Care Research (NF-SI-0515-10079, CDF-2013-06-035, 16/35/01)
- Universiteit van Amsterdam
- KU Leuven
- Novo Nordisk
- Roche Diabetes Care
- National Institutes of Health (UL1TR001863)
- U.S. Food and Drug Administration
- Abbott Diabetes Care
- National Cancer Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- continuous glucose monitoring, time in range, glycemic targets, diabetes management, clinical guidelines
- MeSH terms
- Data Accuracy, Blood Glucose, Data Interpretation, Statistical, Diabetes Mellitus, Glycated Hemoglobin, Humans, Patient Care Planning, Reference Values, Time Factors, Blood Glucose Self-Monitoring, Practice Guidelines as Topic, Internationality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.